Abstract: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.

Abstract: The present invention relates to a method of preparation of a biomaterial containing at least one bioactive molecule from a base biomaterial, characterized by the following successive operations carried out on the aforesaid base biomaterial: a) application of a solid mixture of: cyclodextrin(s) and/or cyclodextrin derivative(s) and/or cyclodextrin inclusion complex(es) and/or cyclodextrin derivative inclusion complex(es), at least one poly(carboxylic) acid, and optionally a catalyst; b) heating at a temperature between 100° C. and 220° C. for a period of 1 to 60 minutes; c) washing with water; d) drying, and wherein at least one bioactive agent is incorporated in the biomaterial by impregnation of the biomaterial after the drying step in a concentrated solution of bioactive agent.

Abstract: The invention provides novel pellets adapted for biologically active preparations and a novel process for preparing said pellets. The novel pellets are adapted for use in the delivery of a biologically active agent. The pellets have an inner zone comprising a plurality of micropellets which are bound together to form a pellet when the micropellets are dispersed in a matrix of an inert pharmaceutical excipient, a biologically active agent and optionally having an outer zone comprising a surface layer comprising a pharmaceutical excipient with or without a biologically active agent. The pellets will have an arcuate surface due to the manner in which they are formed.

Abstract: A method of preparing polysaccharide glassy microparticles which are less than 10 ?um in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 ?m in diameter containing delicate agents can be formed.

Abstract: The invention relates to a wound dressing, a wound contact layer and a medicinal composition comprising a hydrophilic base in which hydrocolloids are dispersed, wherein the hydrophilic base comprises at least one emulsifier and the use of said composition is for the treatment of wounds

Abstract: Personal care compositions an emulsion has an oil phase, a water phase, and a mixed hydrophobe, non-ionic, water-soluble, hydrophobically modified polysaccharide composition comprising a non-ionic water-soluble polysaccharide backbone having at least one C3-C8 short chain hydrophobic group and at least one C9-C24 long chain hydrophobic group attached thereon. This emulsion can be used in a variety of end use applications including textiles, leather, metal treatments, food, pharmaceuticals, paints, agricultural chemicals, polymerization, cleaning and polishing applications, and ore and petroleum recovery. In particular the emulsion is of use in personal care formulation where the emulsion is a component of a vehicle system of the formulation. At least one active personal care ingredient or electrolytes is also present.

Abstract: A method of producing microparticles having a median diameter up to 100 ?m and the microparticles so produced are described. The method includes the steps of providing a solvent having a bioactive dispersed or dissolved therein and a vehicle dissolved therein, carrying out an emulsification in a non-solvent phase to produce an emulsion containing the bioactive and the vehicle in a solvent phase, and evaporating the solvent to leave the microparticles, wherein a mixture of at least two surfactants is employed to stabilize the emulsion and wherein the mixture has a hydrophilic-lipophilic balance (HLB) of up to 8.

Abstract: Stabilized pharmaceutical compositions comprising polymorphs of active pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions.

Abstract: An excipient and a method for manufacturing concentrated Chinese herbs through using the excipient are provided. The manufacturing method includes the following steps: (a) providing a Chinese herb raw material; (b) obtaining an extract from the Chinese herb raw material; (c) collecting volatile oils in a separate bin, later reintroduced; (d) removing water from the extract, to get a concentrate; and (e) adding an excipient to the concentrate, and then granulating and drying, to get a Chinese herbal preparation, in which the excipient contains a capsule protective agent of 1-99 wt % with respect to the excipient and a decomposed product of starch of 1-99 wt % with respect to the excipient. Therefore, the amount of starch required to be used is reduced and the manufactured concentrated Chinese herbal preparation can be completely dissolved in water.

Abstract: The invention relates to a swallowable delivery device fabricated from a composition including a hydrated polymeric matrix with gelatinous consistency, one or more active ingredients, and optionally one or more stiffening agent. The delivery device is of a size and shape amenable to swallowing with enhanced solubility and controlled release of the active ingredients.

Abstract: There exists a strong desire both for pharmaceutical compositions which rapidly exhibit pharmacological effects without an increase in the size of the dosage form or a decline in quality due to interactions between a pharmaceutically active ingredient and the disintegrant, and also for a method of preparing such pharmaceutical compositions. Such a desire is especially acute with regard to, for example, preparations which contain a drug such as an analgesic or a quick-acting hypoglycemic drug that requires the rapid appearance of pharmacological effects following administration, preparations which have a high content of the pharmaceutically active ingredient, and preparations which contain two or more different pharmaceutically active ingredients.

Abstract: A method for the preparation of microcrystalline cellulose containing tablets by roller compaction followed by tabletting is disclosed. A tablet formulation is converted to a dry granulate by roller compaction, and the dry granulate lubricated dry granulate and compacted to a tablet. The tablet formulation comprises at least one active, an microcrystalline cellulose containing material, and, optionally other pharmaceutically acceptable excipients. The microcrystalline cellulose containing material has a maximum primary compaction tensile strength of at least 9 MPa or at least 9.5 MPa and a secondary compaction tensile strength of at least 5 MPa, at least 5.5 MPa, or at least 6 MPa. A method for evaluating binders is also disclosed.

Abstract: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.

Abstract: The deposition of a benefit agent on a substrate after treatment of the substrate with a personal care composition which has a viscosity of at least 50 mPa·s at 25° C. and comprises the benefit agent and a low molecular weight surfactant is improved when a water-soluble polymer is used as a substitute for at least a portion of the low molecular weight surfactant. The headspace concentration of a fragrance provided by such personal care composition is also increased.

Abstract: The non-invasive administration of many active ingredients fails with efflux pumps which sharply reduce the active ingredient absorption on mucous membranes. According to the invention, the active ingredient absorption on mucous membranes can be drastically improved by using dosages containing glutathione and/or compounds comprising numerous thiol groups, in addition to the active ingredient(s). Forms of administration such as matrix tablets, capsules, eye drops, or microparticles, containing the cited combination of active ingredients and auxiliary substances, can be used.

Abstract: The invention relates to the field of solid medicaments that are intended for the oral administration of active ingredients. The aim of the invention is to prevent the improper use of solid, oral medicaments for any user other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characturised in that it comprises: A) at least one caking agent; and B) at least one viscosifying agent, such as to prevent the misuse thereof.

Abstract: A system for delivering solute to a target location within a mammalian body, the system including a medical device, a thermosensitive cellulose gel structure over the medical device, and a biologically active solute within said gel structure. The gel structure deswells and expels the biologically active solute with an increase in gel temperature. The invention includes a method of delivering solute to a target location, where the method includes the steps of providing a thermosensitive cellulose gel structure, wherein the gel structure is loaded with a solute; positioning the loaded gel structure to the target location; and increasing the temperature of the loaded gel structure.

Abstract: Carotenoid compositions of enhanced solubility and bioavailability are described that contain at least one carotenoid with at least one solubility-enhancing polymer. In one embodiment, the carotenoid is a provitamin A carotenoid such as ?-carotene. In another embodiment the carotenoid is a non-provitamin A carotenoid such as lycopene or lutein. Described methods to produce the bioenhanced products include dry blending and solvent spray drying. In accordance with certain embodiments of the invention, the method includes the steps of providing a mixture comprising the carotenoid, a solubility-enhancing polymer and a solvent and removing the solvent to produce an amorphous form of the carotenoid. Products made by the invention's compositions and methods include pharmaceuticals, nutraceuticals, cosmetic, and personal care products for man and animal.

Abstract: A method of forming particles, comprises accelerating a first stream comprising a first liquid, applying a charging voltage of at most 1.5 kV to the first stream, and vibrating the first stream, to form particles.

Abstract: The present invention is related to the use of glyoxal-free compositions, more particularly, to the use of hydroxyethylcellulose agglomerated with low molecular weight hydroxyethylcellulose in consumer products, in particular, pharmaceutical, personal care (excluding oral care compositions), as well as household care applications.

Abstract: A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.

Abstract: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.

Abstract: Compressible solid tablets comprising from 20 to 38 wt % of an oily or viscous liquid, from 50 to 70 wt % of a cellulose polymer and from 2 to 15 wt % of an hydrophobic coating compound, wherein said particles size is 180 microns or less. For example, the oily or viscous liquid may consist of plant oils or surfactants such as cocamide DEA, cocoamide propyl betaine and or mixtures thereof. The cellulose polymer may be carboxy methyl cellulose, microcrystalline cellulose or mixtures thereof. The coating hydrophobic composition may be silicon dioxide, calcium orthophosphate, magnesium carbonate, aluminum oxide. Compressible solid particles are also disclosed which comprise from 50 to 70 wt % of a crystalline alcohol, from 25 to 45% of a cellulose polymer and from 5 to 18 wt % of a coating hydrophobic compound. For example, the crystalline alcohol may be a polyol such as xylitol, isomaltose, sorbitol, maltitol, starch hydrolysate; a terpene such as thymol, carvacrol or menthol.

Abstract: An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated in a closed capsule assembly. The closed capsule assembly comprises the homeopathic carrier.

Abstract: The present invention provides a method for preparing an orally administrable formulation comprising a biologically active ingredient for controlled release in a neutral or basic environment, which comprises the steps of: (a) dispersing powder ethylcellulose with an average diameter from about 0.1 ?m to about 300 ?m in an aqueous solution to provide an aqueous dispersion, wherein the aqueous dispersion is substantially free of detergent; (b) mixing the biologically active ingredient and the aqueous dispersion obtained in step (a) to provide a mixture; and (c) spray-drying the mixture obtained in step (b) for about 10 seconds to about 2 minutes in a drying chamber at a chamber temperature of about 45° C. to about 100° C. to obtain the orally administrable formulation. An orally administrative formulation prepared by the method of the invention is also provided.

Abstract: A highly porous, fast-disintegrating binder suitable for pharmaceutical applications and methods of making the same are disclosed, the binder comprising microporous particles of an aqueous-soluble cellulosic polymer and a wicking agent. Pharmaceutical compositions and fast-disintegrating dosage forms containing the binder are also disclosed.

Abstract: This invention is directed to novel ocular agent delivery systems and, in particular, emulsions and molecular dispersions in the form of a gel comprising a hydrophobic ocular agent.

Abstract: The present invention contemplates a dual warming and moisturizing composition comprising a hydrous portion comprising water and an anhydrous portion comprising a zeolite a carrier and a suspending or dispersing agent, wherein the anhydrous portion and the hydrous portion are combined in use to provide warming and moisturizing effects without the addition of external water.

Abstract: A pharmaceutical composition comprises a pharmaceutically effective amount of an active ingredient and low crystallinity cellulose having a crystallinity index of less than about 75% as measured by X-ray diffraction. The compositions advantageously may be provided in tablet form or granulate form and provide good stability against moisture degradation.

Abstract: The invention provides a film coated solid oral dosage form. The coated form comprises a solid core and at least two separately applied coatings or layers. The first layer, which is a seal coat, contains a swellable polymer, such as hydroxypropyl methyl cellulose. The second layer, which is a release coat, contains carrageenan, microcrystalline cellulose, hydroxypropyl methyl cellulose, and taste modifying agents. In an embodiment the coating contains readily releasable volatile and non-volatile flavoring and cooling agents together with sweeteners, to provide an intense cooling effect which is instantly perceived by the consumer upon placing the dosage form in the oral cavity.

Abstract: The present invention relates to a composition for bone-filling, more particularly, to a bone-filling composition for stimulating bone-formation and bone consolidation comprising calcium sulfate and viscous biopolymers. The composition of the present invention can easily be administered into the missing part of injured bone. Since the composition of the present invention does not diffuse to surrounding organs, it can effectively be used for bone-filling material suitable for body.

Abstract: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Abstract: The present invention relates to a composition having a lubricant effect for use in particular during human vaginal delivery.

Abstract: Aggregates of cellulose-containing particles, such as particles of waste paper and optional other vegetation or waste particles are used as a carrier for additives such as insecticides, herbicides, fertilizers and nutrients. The particles can be also used as a carrier for insect repellants, preferably naturally occurring insect repellants, to repel insects from rooms, buildings, plants, and outdoor areas, and to carry adhered seeds onto an area to be planted with seeds.

Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.

Abstract: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.

Abstract: The present invention concerns an extended release formulation having an accelerating erosion and/or dissolution rate of the surface of the formulation. The formulation comprises a drug having low solubility in water dispersed or dissolved in at least one erasable hydrophilic polymeric matrix.

Abstract: Provided are a solid dosage form comprising an enteric solid dispersion that allows a drug in the preparation to be rapidly dissolved without compromising the solubility of the solid dispersion, and a method for producing the same. More specifically, provided is a solid dosage form comprising an enteric solid dispersion comprising a poorly soluble drug, an enteric polymer and a disintegrant, wherein the disintegrant is low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.0 m2/g. Moreover, provided is a method for producing a solid dosage form comprising an enteric solid dispersion, the method comprising steps of: spraying an enteric polymer solution in which a poorly soluble drug has been dispersed or dissolved, on a powder of low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.

Abstract: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

Abstract: Provided are a solid dosage form comprising a solid dispersion that allows a drug in the preparation to be rapidly dissolved without compromising the solubility of the solid dispersion, and a method for producing the same. More specifically, provided is a solid dosage form comprising a solid dispersion, the dispersion comprising: a poorly soluble drug, a water-soluble polymer and a disintegrant, wherein the disintegrant is low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.0 m2/g. Moreover, provided is a method for producing a solid dosage form comprising a solid dispersion, the method comprising steps of: spraying a water-soluble polymer solution in which a poorly soluble drug has been dispersed or dissolved, on a powder of low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.

Abstract: The invention provides a method of producing a gelled foam comprising the steps of: forming a dispersion by mixing i) a solution comprising a soluble polysaccharide and a plasticizer and adding a polysaccharide/gel-forming ion particles or ii) a soluble, preferably immediately soluble, polysaccharide, preferably an alginate, a polysaccharide/gel-forming ion particles, and adding a solvent, said dispersion (ii) further comprising a water soluble plasticizer to make the dispersion and then aerating the dispersion to form the foam. The foam may be inhomogeneous in structure which is useful in providing improved delivery of a component carried in the foam and in degradation.

Abstract: The present invention relates to improved methods for delivering bioadhesive, bioresorbable, anti-adhesion compositions. Antiadhesion compositions can be made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkylene oxides, multivalent cations and/or polycations. The polymers are associated with each other, and are then used as fluids, gels or foams. By providing a product bag, the compositions can be delivered as gels or as sprays. By dissolving propellant gases in the compositions, the materials can be delivered as foams, which have decreased density, and therefore can adhere to surfaces that previously have been difficult to coat with antiadhesion gels. Delivery systems can also provide mechanisms for expelling more product, and for directing the flow of materials leaving the delivery system. Bioresorbable, bioadhesive, anti-adhesion, and/or hemostatic compositions are useful in surgery to prevent the formation and reformation of post-surgical adhesions.

Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents; R2 represents hydrogen, hydroxy, methoxy or ethoxy; and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier, provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder

Abstract: The present invention relates to improved methods for filling the skin for cosmetic or medical purposes. Compositions comprising carboxymethyl cellulose (CMC), polyethylene oxide (PEO) and calcium ions can be made and have physical properties that depend on the amounts and types of CMC, PEO, and calcium ions to form ioniclaly cross-linked gels. Compositions can be formed into microspheres, coascervates, gels, or membranes. Gels, microspheres and coascervates can be injected directly into a site for dermal filling. Membranes can be surgically introduced, where they swell to form hydrated gels. After introduction, the dermal filler persists for a period of time and then can disintegrate and be removed from the body.

Abstract: The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and/or an agent which inhibits intestinal drug degradation, wherein erosion of the erodible matrix, permits synchronous release of the drug, the hydrogel and the intestinal drug absorption agent and/or the agent which inhibits intestinal drug degradation.

Abstract: The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in the prevention and treatment of gastrointestinal diseases and/or disorders.

Abstract: The present invention relates to a rapidly disintegrating tablet for oral administration. The tablet has a first phase and a second phase blended with the first phase. The first phase has a compacted mixture of methylcellulose having a viscosity of >1000 centipoise and a diluent. The methylcellulose is the sole active ingredient in the first phase. There is also a process for preparing a rapidly disintegrating tablet.

Abstract: The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with ?-cyclodextrin in an aqueous complexation medium comprising ?-cyclodextrin and a negatively- or positively-charged compound which forms an inclusion or non-inclusion complex with ?-cyclodextrin and its inclusion complexes.

Abstract: A tablet for oral administration of nutritional indium comprises about 10–50 mg indium sulfate, about 4–20 mg caffeine, about 2–10% by weight cocoa powder, and about 5–10% by weight ethyl cellulose, in combination with about 50–150 ?g of each of zinc oxide, copper (II) oxide, magnesium oxide, potassium iodide, selenium amino acid chelate, chromium amino acid chelate and manganese amino acid chelate.